Three times is not the charm. New York-based Ophthotech Corporation announced that its Fovista (pegpleranib) failed yet another Phase III clinical trial.
Carlsbad, Calif.-based Ionis Pharmaceuticals announced that GlaxoSmithKline declined its options on both inotersen and IONIS-FB-Lrx, which gives Ionis back control of those rights.
Researchers are warning consumers to be wary of doctors who claim to be able to cure illness using stem cells after three women, at least two who thought they were enrolling in a government-registered trial, were left legally blind when the unproven therapy failed.
Regeneron Pharmaceuticals’ combo therapy containing its flagship eye drug, Eylea, was inferior to Eylea alone in a mid-stage trial involving patients with wet AMD.